SCHEMBL12096685

SCHEMBL12096685

CC(C)(C)c1cccc(S(=O)(=O)n2c(Cc3ccc(C(=O)O)cc3)cc3cccc(F)c32)c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RXRA P19793 3/20 0.39
▸ RXRB P28702 2/20 0.39
▸ RARA P10276 1/20 0.37
▸ RARB P10826 1/20 0.37
▸ RARG P13631 1/20 0.37
▸ HDAC3 O15379 1/20 0.37
▸ HDAC11 Q96DB2 1/20 0.37
▸ HDAC8 Q9BY41 1/20 0.37
▸ HDAC6 Q9UBN7 1/20 0.37
▸ RORC P51449 2/20 0.36
▸ RXRG P48443 1/20 0.36
▸ TAS2R14 Q9NYV8 2/20 0.35
▸ PPARG P37231 1/20 0.35
▸ ACHE P22303 1/20 0.35
▸ CCR2 P41597 1/20 0.34
▸ TRPM8 Q7Z2W7 2/20 0.34
▸ TDP1 Q9NUW8 1/20 0.34
▸ NR1H4 Q96RI1 2/20 0.34
▸ PTGER2 P43116 2/20 0.34
▸ EPHX2 P34913 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12096845 0.85 PPARG (0.42) RXRARXRBHDAC3HDAC11HDAC8
SCHEMBL12096747 0.83 PPARG (0.46) RXRARXRBHDAC3HDAC11HDAC8
SCHEMBL12096889 0.83 PPARG (0.50) RXRARXRBRARARARBRARG
SCHEMBL12096713 0.81 PPARG (0.53) RORCPPARG
SCHEMBL12096640 0.81 RORC (0.46) HDAC3HDAC11HDAC8HDAC6RORC
SCHEMBL12096873 0.80 PPARG (0.41) RXRARXRBHDAC3HDAC11HDAC8
SCHEMBL14054035 0.79 TRPM8 (0.44) RORCPPARGTRPM8NR1H4
SCHEMBL14053489 0.78 TP53 (0.39) RXRARXRBRARARARBRARG
SCHEMBL12096610 0.76 RXRA (0.41) RXRARXRBRARARARBRARG
SCHEMBL12096707 0.74 PPARG (0.51) RORCPPARGNR1H4EPHX2CPT2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120232070-A1 Use of Indole Derivatives as Nurr-1 Activators for the Application Thereof as a Medicament for the Treatment of Parkinson's Disease LABORATOIRES FOURNIER SA (FR) 2012-09-13 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120232070-A1 Use of Indole Derivatives as Nurr-1 Activators for the Application Thereof as a Medicament for the Treatment of Parkinson's Disease NCOR1, NR0B1, MTNR1A RXRA 205/4885RXRB 192/4885RARA 751/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback